OLD National Bancorp IN Sells 1,300 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

OLD National Bancorp IN lowered its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 27.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,500 shares of the biopharmaceutical company’s stock after selling 1,300 shares during the period. OLD National Bancorp IN’s holdings in Intra-Cellular Therapies were worth $462,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB grew its stake in Intra-Cellular Therapies by 124.3% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 133 shares in the last quarter. M&T Bank Corp boosted its position in shares of Intra-Cellular Therapies by 2.2% during the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock worth $526,000 after acquiring an additional 138 shares in the last quarter. CIBC Asset Management Inc boosted its position in shares of Intra-Cellular Therapies by 5.3% during the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 150 shares in the last quarter. Arizona State Retirement System increased its stake in Intra-Cellular Therapies by 0.8% in the fourth quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock valued at $2,302,000 after acquiring an additional 206 shares during the last quarter. Finally, Tidal Investments LLC increased its stake in Intra-Cellular Therapies by 4.5% in the fourth quarter. Tidal Investments LLC now owns 5,027 shares of the biopharmaceutical company’s stock valued at $420,000 after acquiring an additional 215 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.87 on Tuesday. Intra-Cellular Therapies, Inc. has a 12-month low of $66.26 and a 12-month high of $131.98. The business has a 50-day simple moving average of $131.87 and a two-hundred day simple moving average of $119.22. The stock has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Cantor Fitzgerald reissued a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Wall Street Zen started coverage on Intra-Cellular Therapies in a research report on Thursday, May 15th. They set a “hold” rating for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Eleven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.